Drug Trial Radar · NCT06956196
Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: May 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
May 2025
Primary completion
May 2026
Study completion Aug 2026
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- May 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, Pharmacokinetics(PK), PharmacoDynamics(PD) and immunogenicity of Stapokibatrt in children with moderate-to-severe atopic dermatitis.
Conditions
- Atopic Dermatitis
Interventions
StapokibatrtBiological
Stapokibatrt 1 or 2 ml,Subcutaneous injection(SC)
PlaceboOther
Placebo of matching volume,Subcutaneous injection(SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects achieving Eczema Area and Severity Index(EASI-75) at week 18Time frame: Up to week 18
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Children's Hospital Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.